Asperulosidic acid

Asperulosidic acid
Product Name Asperulosidic acid
CAS No.: 25368-11-0
Catalog No.: CFN92108
Molecular Formula: C18H24O12
Molecular Weight: 432.4 g/mol
Purity: >=98%
Type of Compound: Iridoids
Physical Desc.: Powder
Targets: EGFR | AP-1
Source: The herbs of Hedyotis diffusa Willd.
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Price: $318/20mg
Asperulosidic acid has been recently used in chinese medicine as a useful drug against some tumors. It has anticlastogenic activity, since the anticlastogenic irridoids have an alpha-unsaturated carbonyl group, this structure is considered to play an important role in the anticlastogenicity. Asperulosidic acid can inhibit the seed germination and growth of seedlings of large crabgrass. Asperulosidic acid, and 6-O-(beta-D-glucopyranosyl)-1-O-octanoyl-beta-D-glucopyranose are effective in suppressing 12-O-tedtradecanoylphorbol-13-acetate (TPA)- or epidermal growth factor (EGF)-induced cell transformation and associated AP-1 activity.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Exp Biol Med (Maywood).2019, 244(16):1463-1474
  • TCI CO.2019, US20190151281A1
  • PLoS One.2017, 12(8):e0181191
  • Environ Toxicol.2019, 34(4):513-520.
  • Toxicol In Vitro.2018, 52:94-105
  • Dis Markers.2022, 2022:2380879.
  • Front Plant Sci.2020, 10:1705
  • Heliyon.2023, e12684.
  • J Nat Prod.2017, 80(4):854-863
  • Microchemical Journal2023. 191:108938
  • Loganic acid

    Catalog No: CFN98212
    CAS No: 22255-40-9
    Price: $50/20mg
    Alboside I

    Catalog No: CFN95752
    CAS No: 239791-85-6
    Price: $318/10mg
    Gentiournoside D

    Catalog No: CFN90979
    CAS No: 157722-21-9
    Price: $388/5mg
    Shanzhiside

    Catalog No: CFN98370
    CAS No: 29836-27-9
    Price: $318/20mg
    Negundoside

    Catalog No: CFN70455
    CAS No: 82451-20-5
    Price: Inquiry(manager@chemfaces.com)
    Monotropein

    Catalog No: CFN99523
    CAS No: 5945-50-6
    Price: $90/20mg
    Adoxosidic acid

    Catalog No: CFN89313
    CAS No: 84375-46-2
    Price: Inquiry(manager@chemfaces.com)
    Suspenoidside B

    Catalog No: CFN95071
    CAS No: 2161432-08-0
    Price: $413/5mg
    Geniposidic acid

    Catalog No: CFN98337
    CAS No: 27741-01-1
    Price: $30/20mg
    Scandoside

    Catalog No: CFN92535
    CAS No: 18842-99-4
    Price: Inquiry(manager@chemfaces.com)
    Yakugaku Zasshi. 1981 Jul;101(7):657-9.
    Two novel glycosides from the fruits of Morinda citrifolia (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line.[Pubmed: 11479211]
    The fruit juice of Morinda citrifolia (noni), a plant originally grown in the Hawaiian and Tahitian islands, has long been used by islanders to treat diseases, including cancer.
    METHODS AND RESULTS:
    Two novel glycosides, 6-O-(beta-D-glucopyranosyl)-1-O-octanoyl-beta-D-glucopyranose and Asperulosidic acid, extracted from the juice of noni fruits, were used to examine their effects on 12-O-tedtradecanoylphorbol-13-acetate (TPA)- and epidermal growth factor (EGF)-induced AP-1 transactivation and cell transformation in mouse epidermal JB6 cells.
    CONCLUSIONS:
    The results indicated that both compounds were effective in suppressing TPA- or EGF-induced cell transformation and associated AP-1 activity. TPA- or EGF-induced phosphorylation of c-Jun, but not extracellular signal-regulated kinases or p38 kinases, was also blocked by the compounds, indicating that c-Jun N-terminal kinases were critical in mediating TPA- or EGF-induced AP-1 activity and subsequent cell transformation in JB6 cells.
    J.Weed Sci.Tech., 1986, 31:280-6.
    Plant Growth Inhibitors in Catchweed Seeds and Their Allelopathy.[Reference: WebLink]

    METHODS AND RESULTS:
    Two Asp-related iridoidglucosides, compounds A and B were isolated from the dormant seeds of catchweed. By chemical analysis, compound A was identified as Asperulosidic acid which was derived from Asp through the cleavage of a lactone ring, and compound B as deacetyl Asperulosidic acid produced through the deacetylation of Asperulosidic acid. Asperulosidic acid inhibited the seed germination and growth of seedlings of large crabgrass and alfalfa to the same degree as Asp, but did not inhibit white clover, while deacetyl Asperulosidic acid showed lower inhibitory effect on the tested plants than Asp and Asperulosidic acid. Furthermore, Asperulosidic acid showed similar inhibitory activity to Asp on the germination of catchweed seeds themselves.
    CONCLUSIONS:
    Since these compounds were only detected in the exudate obtained from the seed coat of catchweed seeds, inhibition of the germination and growth of lettuce placed together with catchweed seeds may be due to iridoidglucosides liberated from the latter seeds which have been soaked in water.
    Phytomedicine . 2019 Feb;53:274-285.
    Anti-renal fibrosis effect of asperulosidic acid via TGF-β1/smad2/smad3 and NF-κB signaling pathways in a rat model of unilateral ureteral obstruction[Pubmed: 30668407]
    Abstract Background: Renal fibrosis is the most common pathway leading to end-stage renal disease. It is characterized by excess extracellular matrix (ECM) accumulation and renal tissue damage, subsequently leading to kidney failure. Asperulosidic acid (ASPA), a bioactive iridoid glycoside, exerts anti-tumor, anti-oxidant, and anti-inflammatory activities, but its effects on renal fibrosis induced by unilateral ureteral obstruction (UUO) have not yet been investigated. Purpose: This study aimed to investigate the protective effect of ASPA on renal fibrosis induced by UUO, and to explore its pharmacological mechanism. Methods: Thirty-six Sprague-Dawley (SD) rats were randomly divided into six groups: sham group, UUO model group, three ASPA treatment groups (10, 20, and 40 mg/kg), and captopril group (20 mg/kg). Rats were administered vehicle, ASPA or captopril intraperitoneally once a day for 14 consecutive days. Urea nitrogen (BUN), uric acid (UA) and inflammatory factors in serum samples were evaluated on the 7th, 10th, and 14th day after renal fibrosis induction. In addition, the 12 h urine was collected to test the content of urinary protein (upro) on the 14th day. The obstructive renal tissues were collected for pathological analysis (hematoxylin and eosion (H&E) staining and Masson's Trichrome staining) and immunohistochemical analysis on the 14th day after renal fibrosis induction. The mRNA expression of related factors and the protein levels of smad2, smad3, and smad4 were measured in UUO-induced rats by real time PCR and Western blot, respectively. Results: The levels of BUN, UA, and upro were elevated in UUO-induced rats, but ASPA treatment improved renal function by reducing the levels of BUN, UA, and upro. The protein levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-6, as well as the mRNA levels of TNF-α, IL-1β, IL-6, monocyte chemoattractant protein-1 (MCP-1) and interferon-γ (IFN-γ), were decreased after ASPA administration (10, 20 and 40 mg/kg) in a dose-dependent manner. The ASPA exerted an alleviation effect on the inflammatory response through inhibition of nuclear factor-kappa B (NF-κB) pathway. In addition, reductions in α-smooth muscle actin (α-SMA), collagen III, and fibronectin expression were observed after ASPA administration at doses of 20 and 40 mg/kg. Furthermore, the renal expression of transforming growth factor-β1 (TGF-β1), smad2, smad3, and smad4 was down-regulated by ASPA treatment at doses of 20 and 40 mg/kg. Conclusion: ASPA possessed protective effects on renal interstitial fibrosis in UUO-induced rats. These effects may be through inhibition of the activation of NF-κB and TGF-β1/smad2/smad3 signaling pathways. Keywords: Asperulosidic acid; NF-κB signaling pathway; Renal interstitial fibrosis; TGF-β1/smad2/smad3 pathway; Unilateral ureteral obstruction (UUO).
    Int J Mol Sci . 2018 Jul 12;19(7):2027.
    Asperuloside and Asperulosidic Acid Exert an Anti-Inflammatory Effect via Suppression of the NF-κB and MAPK Signaling Pathways in LPS-Induced RAW 264.7 Macrophages[Pubmed: 30002289]
    Abstract Hedyotis diffusa is a folk herb that is used for treating inflammation-related diseases in Asia. Previous studies have found that iridoids in H. diffusa play an important role in its anti-inflammatory activity. This study aimed to investigate the anti-inflammatory effect and potential mechanism of five iridoids (asperuloside (ASP), Asperulosidic acid (ASPA), desacetyl Asperulosidic acid (DAA), scandoside methyl ester (SME), and E-6-O-p-coumaroyl scandoside methyl ester (CSME)) that are presented in H. diffusa using lipopolysaccharide (LPS)-induced RAW 264.7 cells. ASP and ASPA significantly decreased the production of nitric oxide (NO), prostaglandin E₂ (PGE₂), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in parallel with the inhibition of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-α, and IL-6 mRNA expression in LPS-induced RAW 264.7 cells. ASP treatment suppressed the phosphorylation of the inhibitors of nuclear factor-kappaB alpha (IκB-α), p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK). The inhibitory effect of ASPA was similar to that of ASP, except for p38 phosphorylation. In summary, the anti-inflammatory effects of ASP and ASPA are related to the inhibition of inflammatory cytokines and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways, which provides scientific evidence for the potential application of H. diffusa. Keywords: anti-inflammation; iridoids; mitogen-activated protein kinase; nuclear factor-kappaB.
    Glucoliquiritin

    Catalog No: CFN95011
    CAS No: 93446-18-5
    Price: $318/10mg
    Dehydrojuncusol

    Catalog No: CFN95143
    CAS No: 117824-04-1
    Price: $318/5mg
    Leachianol F

    Catalog No: CFN95147
    CAS No: 164123-50-6
    Price: $318/5mg
    Methylgomisin O

    Catalog No: CFN95236
    CAS No: 1276654-07-9
    Price: $318/5mg
    Phyllanthusiin C

    Catalog No: CFN95260
    CAS No: 142674-52-0
    Price: $318/5mg
    Isorhamnetin-3-O-rutinoside-7-O-glucoside

    Catalog No: CFN95494
    CAS No: 55481-91-9
    Price: $318/5mg
    Campneoside II

    Catalog No: CFN95498
    CAS No: 95587-86-3
    Price: $318/10mg
    Ganoweberianic acid E

    Catalog No: CFN95504
    CAS No: 1309931-90-5
    Price: $413/5mg
    Ganoderenic acid G

    Catalog No: CFN95517
    CAS No: 120481-73-4
    Price: $318/5mg
    Ganoderic acid GS-2

    Catalog No: CFN95549
    CAS No: 1206781-65-8
    Price: $413/5mg